A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial

BACKGROUND: The COVID-19 pandemic has imposed an enormous burden on health care systems around the world. In the past, the administration of convalescent plasma of patients having recovered from SARS and severe influenza to patients actively having the disease showed promising effects on mortality a...

Descripción completa

Detalles Bibliográficos
Autores principales: Devos, Timothy, Geukens, Tatjana, Schauvlieghe, Alexander, Ariën, Kevin K., Barbezange, Cyril, Cleeren, Myriam, Compernolle, Veerle, Dauby, Nicolas, Desmecht, Daniël, Grimaldi, David, Lambrecht, Bart N., Luyten, Anne, Maes, Piet, Moutschen, Michel, Romano, Marta, Seyler, Lucie, Nevessignsky, Michel Toungouz, Vandenberghe, Katleen, van Griensven, Johan, Verbeke, Geert, Vlieghe, Erika, Yombi, Jean Cyr, Liesenborghs, Laurens, Verhamme, Peter, Meyfroidt, Geert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7691949/
https://www.ncbi.nlm.nih.gov/pubmed/33246499
http://dx.doi.org/10.1186/s13063-020-04876-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7691949/
https://www.ncbi.nlm.nih.gov/pubmed/33246499
http://dx.doi.org/10.1186/s13063-020-04876-0

Ejemplares similares